Skip to main content

Advertisement

Table 3 Association between VEGF and eNOS polymorphisms and overall survival (OS)

From: eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial

Polymorphisms CT + B CT
Median OS (95% CI) HR (95% CI) P* Median OS (95% CI) HR (95% CI) P*
VEGF −2578
 AA 26.1 (9.0–34.5) 1.05 (0.61–1.81)   24.0 (14.4–36.7) 1.11 (0.67–1.85)  
 CC/CA 21.4 (19.3–27.2) 1.00 0.854 20.8 (19.2–24.5) 1.00 0.671
VEGF −1498
 CC 26.1 (10.4–33.1) 1.12 (0.66–1.91)   26.6 (14.4–36.7) 0.95 (0.56–1.59)  
 TT/CT 21.8 (19.3-27.2) 1.00 0.664 20.8 (18.8–24.3) 1.00 0.834
VEGF −1154
 AA 21.8 (2.3–30.4) 1.18 (0.53–2.63)   20.2 (11.1–29.2) 1.92 (0.96–3.85)  
 GA/GG 21.4 (14.6–28.8) 1.00 0.686 25.2 (19.2–29.1) 1.00 0.066
VEGF −634
 GC 19.3 (13.1–22.0) 1.54 (0.98–2.44)   20.2 (16.8–24.3) 1.18 (0.76–1.82)  
 GG/CC 29.1 (20.9–33.5) 1.00 0.064 24.3 (20.2–29.2) 1.00 0.456
VEGF +936
 TT 8.6 (7.9–13.9) 5.48 (1.60–18.8)   28.0 (–) 0.96 (0.11–7.98)  
 CT/CC 22.7 (20.5–27.5) 1.00 0.007 21.3 (19.2–25.2) 1.00 0.967
eNOS +894
 GT 20.1 (12.0–23.2) 1.80 (1.12–2.89)   24.3 (17.9–28.6) 0.82 (0.53–1.25)  
 GG/TT 26.1 (21.0–33.5) 1.00 0.014 21.3 (19.2–26.4) 1.00 0.356
eNOS VNTR
 4bb 24.8 (20.1–34.5) 0.54 (0.33–0.89)   23.6 (19.9–28.0) 0.76 (0.46–1.23)  
 4ab/4aa 20.6 (13.7–24.7) 1.00 0.015 20.1 (15.0–23.3) 1.00 0.259
eNOS −786
 CC 27.2 (14.6–33.5) 0.97 (0.53–1.80)   20.4 (16.0–21.7) 1.40 (0.77–2.55)  
 CT/TT 21.3 (16.4–27.4) 1.00 0.931 23.6 (19.9–28.0) 1.00 0.270
  1. *Adjusted for CT (FOLFOX4/FOLFIRI), gender, age, KRAS status, tumor localization (rectum/colon).